Genetic Signatures (ASX:GSS) YoY EPS Growth: 59.42% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures YoY EPS Growth?

Genetic Signatures ASX:GSS +6.78% YoY EPS Growth is 59.42% as of Dec. 2025. The stock has 4 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Genetic Signatures's YoY EPS Growth for the quarter that ended in Dec. 2025 was 59.42%.

Genetic Signatures's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was A$-0.03.

Genetic Signatures YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures YoY EPS Growth Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.00 75.00 -557.14 -12.50 17.59

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.91 32.69 5.48 42.86 59.42

Genetic Signatures YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Genetic Signatures's YoY EPS Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EPS Growth (A: Jun. 2025 )
=(Earnings per Share (Diluted) (A: Jun. 2025 )-Earnings per Share (Diluted) (A: Jun. 2024 ))/ | Earnings per Share (Diluted) (A: Jun. 2024 ) |
=(-0.089--0.108)/ | -0.108 |
=17.59 %

Genetic Signatures's YoY EPS Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EPS Growth (Q: Dec. 2025 )
=(Earnings per Share (Diluted) (Q: Dec. 2025 )-Earnings per Share (Diluted) (Q: Dec. 2024 )) / | Earnings per Share (Diluted) (Q: Dec. 2024 )) |
=(-0.028--0.069)/ | -0.069 |
=59.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 59.42% mean?
Genetic Signatures (ASX:GSS) has a YoY EPS Growth of 59.42% as of Dec. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Genetic Signatures and its competitors.
Is Genetic Signatures' YoY EPS Growth too high?
Genetic Signatures' current YoY EPS Growth is 59.42%.
How does Genetic Signatures' YoY EPS Growth compare to TMO and DHR?
Genetic Signatures' YoY EPS Growth of 59.42% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Diagnostics & Research company?
A good YoY EPS Growth depends on the Medical Diagnostics & Research industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Genetic Signatures and its competitors. Genetic Signatures's current YoY EPS Growth is 59.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.39, compared to a current price of A$0.06 — trading 83.8% below its estimated fair value. The current YoY EPS Growth is 59.42%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current YoY EPS Growth is 59.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.